168 related articles for article (PubMed ID: 33642281)
1. Preliminary Study of hsa-mir-626 Change in the Cerebrospinal Fluid in Parkinson's Disease.
Qin LX; Tan JQ; Zhang HN; Tang JG; Jiang B; Shen XM; Guo JF; Tan LM; Tang B; Wang CY
Neurol India; 2021; 69(1):115-118. PubMed ID: 33642281
[TBL] [Abstract][Full Text] [Related]
2. Preliminary study of hsa-miR-626 change in the cerebrospinal fluid of Parkinson's disease patients.
Qin LX; Tan JQ; Zhang HN; Tang JG; Jiang B; Shen XM; Tang BS; Wang CY
J Clin Neurosci; 2019 Dec; 70():198-201. PubMed ID: 31492481
[TBL] [Abstract][Full Text] [Related]
3. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.
Gui Y; Liu H; Zhang L; Lv W; Hu X
Oncotarget; 2015 Nov; 6(35):37043-53. PubMed ID: 26497684
[TBL] [Abstract][Full Text] [Related]
4. Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson's disease.
Uwatoko H; Hama Y; Iwata IT; Shirai S; Matsushima M; Yabe I; Utsumi J; Sasaki H
Mol Brain; 2019 May; 12(1):49. PubMed ID: 31088501
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy.
Marques TM; Kuiperij HB; Bruinsma IB; van Rumund A; Aerts MB; Esselink RAJ; Bloem BR; Verbeek MM
Mol Neurobiol; 2017 Dec; 54(10):7736-7745. PubMed ID: 27844283
[TBL] [Abstract][Full Text] [Related]
6. The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes.
Starhof C; Hejl AM; Heegaard NHH; Carlsen AL; Burton M; Lilje B; Winge K
Mov Disord; 2019 Feb; 34(2):246-254. PubMed ID: 30557454
[TBL] [Abstract][Full Text] [Related]
7. Combinatory microRNA serum signatures as classifiers of Parkinson's disease.
Patil KS; Basak I; Dalen I; Hoedt E; Lange J; Lunde KA; Liu Y; Tysnes OB; Forsgren L; Aarsland D; Neubert TA; Larsen JP; Alves G; Møller SG
Parkinsonism Relat Disord; 2019 Jul; 64():202-210. PubMed ID: 31003905
[TBL] [Abstract][Full Text] [Related]
8. Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson's disease.
He S; Huang L; Shao C; Nie T; Xia L; Cui B; Lu F; Zhu L; Chen B; Yang Q
Transl Neurodegener; 2021 Jul; 10(1):25. PubMed ID: 34315539
[TBL] [Abstract][Full Text] [Related]
9. Meta-analyses identify differentially expressed micrornas in Parkinson's disease.
Schulz J; Takousis P; Wohlers I; Itua IOG; Dobricic V; Rücker G; Binder H; Middleton L; Ioannidis JPA; Perneczky R; Bertram L; Lill CM
Ann Neurol; 2019 Jun; 85(6):835-851. PubMed ID: 30990912
[TBL] [Abstract][Full Text] [Related]
10. An investigation of microRNA-103 and microRNA-107 as potential blood-based biomarkers for disease risk and progression of Alzheimer's disease.
Wang J; Chen C; Zhang Y
J Clin Lab Anal; 2020 Jan; 34(1):e23006. PubMed ID: 31420923
[TBL] [Abstract][Full Text] [Related]
11. Circulatory miR-223-3p Discriminates Between Parkinson's and Alzheimer's Patients.
Mancuso R; Agostini S; Hernis A; Zanzottera M; Bianchi A; Clerici M
Sci Rep; 2019 Jun; 9(1):9393. PubMed ID: 31253822
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
[TBL] [Abstract][Full Text] [Related]
13. Can Peripheral MicroRNA Expression Data Serve as Epigenomic (Upstream) Biomarkers of Alzheimer's Disease?
Yılmaz ŞG; Erdal ME; Özge AA; Sungur MA
OMICS; 2016 Aug; 20(8):456-61. PubMed ID: 27501295
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA Profile in Patients with Alzheimer's Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched Cerebrospinal Fluid Samples.
Riancho J; Vázquez-Higuera JL; Pozueta A; Lage C; Kazimierczak M; Bravo M; Calero M; Gonalezález A; Rodríguez E; Lleó A; Sánchez-Juan P
J Alzheimers Dis; 2017; 57(2):483-491. PubMed ID: 28269782
[TBL] [Abstract][Full Text] [Related]
15. Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer's disease.
Jia L; Zhu M; Yang J; Pang Y; Wang Q; Li Y; Li T; Li F; Wang Q; Li Y; Wei Y
BMC Med; 2021 Nov; 19(1):264. PubMed ID: 34775974
[TBL] [Abstract][Full Text] [Related]
16. Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer's disease.
Hara N; Kikuchi M; Miyashita A; Hatsuta H; Saito Y; Kasuga K; Murayama S; Ikeuchi T; Kuwano R
Acta Neuropathol Commun; 2017 Jan; 5(1):10. PubMed ID: 28137310
[TBL] [Abstract][Full Text] [Related]
17. Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease.
Irwin DJ; Fedler J; Coffey CS; Caspell-Garcia C; Kang JH; Simuni T; Foroud T; Toga AW; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Weintraub D; Mollenhauer B; Galasko DR; Siderowf A; Marek K; Trojanowski JQ; Shaw LM;
Ann Neurol; 2020 Sep; 88(3):574-587. PubMed ID: 32542885
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian.
Mo M; Xiao Y; Huang S; Cen L; Chen X; Zhang L; Luo Q; Li S; Yang X; Lin X; Xu P
Oncotarget; 2017 Jan; 8(1):15-28. PubMed ID: 27965467
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
Katayama T; Sawada J; Takahashi K; Yahara O; Hasebe N
Alzheimers Res Ther; 2021 Oct; 13(1):163. PubMed ID: 34610837
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
